01926nas a2200385   4500000000100000008004100001260001300042653001000055653000900065653001900074653001100093653001100104653002300115653001200138653000900150653001600159653002600175653001100201653001800212100001300230700001500243700001500258700001200273700001500285700001400300700001300314700002100327245009900348856005600447300001000503490000700513050001500520520099100535022001401526       2008                            d  c2008 Sep10aAdult10aAged10aCohort Studies10aFemale10aHumans10aLeprostatic Agents10aleprosy10aMale10aMiddle Aged10aRetrospective Studies10aTravel10aUnited States1 aJacob JT1 aKozarsky P1 aDismukes R1 aBynoe V1 aMargoles L1 aLeonard M1 aTellez I1 aFranco-Paredes C00aFive-year experience with type 1 and type 2 reactions in Hansen disease at a US travel clinic.  uhttp://www.ajtmh.org/content/79/3/452.full.pdf+html  a452-40 v79  aJACOB 20083 a<p>Very few data have been reported on the epidemiology and clinical features of leprosy reactions in non-endemic settings. We performed a retrospective descriptive analysis to define the frequency and features of Type 1 and Type 2 leprosy reactions in a cohort of patients followed at a US travel and tropical medicine clinic in a 5-year period. We identified that leprosy reactions presented in 10/14 (71.4%) patients with leprosy seen at our clinic. We identified that leprosy reactions occur frequently among patients living in non-endemic areas and may occur before the initiation of multi-drug therapy (MDT), during MDT, or even years after completion of therapy and may produce significant neurologic sequelae. This group of patients needs long-term clinical monitoring even after completion of MDT because of the need to continue either anti-inflammatory therapy, presence of severe neurologic sequelae after reactions, or the potential occurrence of late leprosy reactions.</p>  a1476-1645